PE20001316A1 - Anticuerpo humanizado especifico para 4-1bb humano y composicion farmaceutica que lo contiene - Google Patents

Anticuerpo humanizado especifico para 4-1bb humano y composicion farmaceutica que lo contiene

Info

Publication number
PE20001316A1
PE20001316A1 PE1999001162A PE00116299A PE20001316A1 PE 20001316 A1 PE20001316 A1 PE 20001316A1 PE 1999001162 A PE1999001162 A PE 1999001162A PE 00116299 A PE00116299 A PE 00116299A PE 20001316 A1 PE20001316 A1 PE 20001316A1
Authority
PE
Peru
Prior art keywords
chain
antigenic
antibody
union
region
Prior art date
Application number
PE1999001162A
Other languages
English (en)
Inventor
Hyo-Jeong Hong
Chang-Yuil Kang
Sung-Kwan Yoon
Sung-Sup Park
Young-Jun Kang
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of PE20001316A1 publication Critical patent/PE20001316A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA COMPOSICION DE UN ANTICUERPO HUMANIZADO QUE COMPRENDE: a)UNA CADENA LIGERA DE UN ANTICUERPO MONOCLONAL QUE TIENE REGIONES DETERMINANTES DE COMPLEMENTARIEDAD DEL DOMINIO DE UNION ANTIGENICA SUSTITUIDO POR REGIONES QUE DETERMINAN LA COMPLEMENTARIEDAD DEL DOMINIO DE UNION ANTIGENICA DE LA CADENA LIGERA DE UN ANTICUERPO MONOCLONAL DE RATON QUE SE UNE ESPECIFICAMENTE A LA PROTEINA H4-1BB; b)UNA CADENA PESADA DE UN ANTICUERPO MONOCLONAL QUE TIENE LAS REGIONES DETERMINANTES DE COMPLEMENTARIEDAD DEL DOMINIO DE UNION ANTIGENICA SUSTITUIDO POR LAS REGIONES QUE DETERMINAN LA COMPLEMENTARIEDAD DEL DOMINIO DE UNION ANTIGENICA DE LA CADENA PESADA DE ANTICUERPO MONOCLONAL DE RATON QUE ESPECIFICAMENTE SE UNE A LA PROTEINA H4-1BB. TAMBIEN SE REFIERE A UN ANTICUERPO HUMANIZADO QUE COMPRENDE: a)UNA REGION DE CADENA LIGERA DE 107 AMINOACIDOS SEQ ID NO 1; b)UNA REGION VARIABLE DE CADENA PESADA DE 119 AMINOACIDOS DE SEQ ID NO 2; c)UNA REGION DE CADENA LIGERA Y PESADA RESPECTIVAMENTE IDENTICA A UNA REGION CONSTANTE DE CADENA LIGERA DE ANTICUERPO HUMANO; TAMBIEN SE REFIERE A UN PLASMIDO QUE COMPRENDE UN POLINUCLEOTIDO CODIFICADOR DE LA REGION VARIABLE O PESADA Y A UNA CELULA HUESPED. LA COMPOSICION PUEDE SER UTIL PARA SUPRIMIR UNA RESPUESTA AUTOINMUNE (ARTRITIS, RECHAZO DE TRASPLANTE), INHIBIR LA ACTIVACION DE CELULA T
PE1999001162A 1998-11-17 1999-11-17 Anticuerpo humanizado especifico para 4-1bb humano y composicion farmaceutica que lo contiene PE20001316A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR19980049177 1998-11-17
KR1019990016750A KR20000034847A (ko) 1998-11-17 1999-05-11 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물

Publications (1)

Publication Number Publication Date
PE20001316A1 true PE20001316A1 (es) 2001-01-19

Family

ID=26634340

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999001162A PE20001316A1 (es) 1998-11-17 1999-11-17 Anticuerpo humanizado especifico para 4-1bb humano y composicion farmaceutica que lo contiene

Country Status (12)

Country Link
US (1) US6458934B1 (es)
EP (1) EP1131357A1 (es)
JP (1) JP2002531383A (es)
KR (2) KR20000034847A (es)
CN (1) CN1187374C (es)
AR (1) AR021296A1 (es)
AU (1) AU757760B2 (es)
CA (1) CA2351170A1 (es)
CO (1) CO5160384A1 (es)
PE (1) PE20001316A1 (es)
TW (1) TWI230163B (es)
WO (1) WO2000029445A1 (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051228A (en) * 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
IL127127A0 (en) * 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
DK1234031T3 (en) 1999-11-30 2017-07-03 Mayo Foundation B7-H1, AN UNKNOWN IMMUNE REGULATORY MOLECULE
KR100468321B1 (ko) * 2001-02-08 2005-01-27 학교법인 울산공업학원 종양 및 에이즈치료용 폴리펩타이드
US7651686B2 (en) 2001-10-09 2010-01-26 Mayo Foundation For Medical Education And Research Enhancement of immune responses by 4-1bb-binding agents
EP2075256A2 (en) 2002-01-14 2009-07-01 William Herman Multispecific binding molecules
KR100452954B1 (ko) * 2002-02-26 2004-10-14 주식회사 엘지생명과학 가변영역 아미노산 치환을 통한 인간 4-1비비분자에 대한결합 특이성이 증가된 변형 인간화 항체의 제조방법
EP1485403A4 (en) * 2002-03-15 2007-08-08 Multicell Immunotherapeutics I COMPOSITIONS AND METHOD FOR INTRODUCTION OR REINFORCEMENT OF ANTIBODY AND MAIN THISTOCOMPATIBILITY CLASS I OR CLASS II RESTRICTED T-CELL REACTIONS USING IMMUNOMODULATING, NON-CODING RNA MOTIVES
US20070037769A1 (en) * 2003-03-14 2007-02-15 Multicell Immunotherapeutics, Inc. Compositions and methods to treat and control tumors by loading antigen presenting cells
EP2258712A3 (en) 2002-03-15 2011-05-04 Multicell Immunotherapeutics, Inc. Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs
CA2492561A1 (en) * 2002-07-15 2004-01-22 Mayo Foundation For Medical Education And Research Treatment and prophylaxis with 4-1bb-binding agents
PL375144A1 (en) * 2002-07-30 2005-11-28 Bristol-Myers Squibb Company Humanized antibodies against human 4-1bb
PL376536A1 (pl) 2002-08-28 2006-01-09 Immunex Corporation Kompozycje i sposoby leczenia chorób układu sercowo-naczyniowego
JP2006522806A (ja) * 2003-03-26 2006-10-05 マルチセル・イミュノセラピューティクス，インコーポレイテッド 細胞死及び／又はアポトーシスを誘導するための、選択されたｒｎａモチーフ
US20040197312A1 (en) 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
US7288638B2 (en) * 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
PT1810026T (pt) 2004-10-06 2018-06-11 Mayo Found Medical Education & Res B7-h1 e pd-1 no tratamento do carcinona de células renais
US7888481B2 (en) * 2005-02-10 2011-02-15 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
CA2597265C (en) * 2005-02-10 2015-03-24 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
US20080019905A9 (en) * 2005-02-18 2008-01-24 Strome Scott E Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
EP2399935A3 (en) * 2005-02-15 2012-02-22 GTC Biotherapeutics, Inc. An anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof
US20060182744A1 (en) * 2005-02-15 2006-08-17 Strome Scott E Anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof
EP2388273B1 (en) * 2005-10-21 2017-07-05 LFB USA, Inc. Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use
KR100883430B1 (ko) 2007-06-13 2009-02-12 한국생명공학연구원 혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도
WO2009134389A2 (en) * 2008-05-01 2009-11-05 Gtc Biotherapeutics, Inc. An anti-cd137 antibody as an agent in the treatment of inflammatory conditions
WO2009135861A2 (en) 2008-05-07 2009-11-12 Novo Nordisk A/S Humanized antibodies against human interferon-alpha
WO2010042433A1 (en) 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
EP2993234B1 (en) 2013-04-30 2018-10-10 Konkuk University Industrial Cooperation Corp. Cmp-acetylneuraminic acid hydroxylase targeting vector, transgenic animal for xenotransplantation introduced with the vector, and method of manufacturing the same
EP3052131B1 (en) 2013-10-01 2018-12-05 Mayo Foundation for Medical Education and Research Methods for treating cancer in patients with elevated levels of bim
KR101503341B1 (ko) 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
US10302653B2 (en) 2014-05-22 2019-05-28 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti B7-H1 antibodies
US10517875B2 (en) 2014-07-23 2019-12-31 Mayo Foundation for Medical Engineering and Research Targeting DNA-PKcs and B7-H1 to treat cancer
US10875926B2 (en) 2015-09-22 2020-12-29 Dingfu Biotarget Co., Ltd. Fully human antibody against human CD 137
WO2017075045A2 (en) 2015-10-30 2017-05-04 Mayo Foundation For Medical Education And Research Antibodies to b7-h1
CN108367075B (zh) * 2016-11-23 2022-08-09 免疫方舟医药技术股份有限公司 4-1bb结合蛋白及其用途
SG10201914064QA (en) * 2017-01-06 2020-03-30 Eutilex Co Ltd Anti-human 4-1 bb antibodies and use thereof
SG10202102897PA (en) 2017-01-20 2021-04-29 Magenta Therapeutics Inc Compositions and methods for the depletion of cd137+ cells
CN111511762A (zh) * 2017-08-21 2020-08-07 天演药业公司 抗cd137分子及其用途
EP3470428A1 (en) * 2017-10-10 2019-04-17 Numab Innovation AG Antibodies targeting cd137 and methods of use thereof
US11578133B2 (en) 2017-10-10 2023-02-14 Namab Therapeutics AG Antibodies targeting CD137 and methods of use thereof
CN109651507B (zh) * 2017-10-12 2021-11-26 瑞阳(苏州)生物科技有限公司 一种激动型4-1bb单克隆抗体
WO2019109238A1 (en) 2017-12-05 2019-06-13 Lyvgen Biopharma Co., Ltd. Anti-cd137 antibodies and uses thereof
RU2020127196A (ru) * 2018-01-22 2022-02-24 Цзянсу Хэнжуй Медицин Ко., Лтд. Антитело против 4-1bb, его антигенсвязывающий фрагмент и его медицинское применение
CN108195815A (zh) * 2018-01-31 2018-06-22 李翀 时间分辨荧光免疫层析法检测amh的试纸条、试剂盒及方法
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
JP7360720B2 (ja) * 2018-04-09 2023-10-13 オリセル セラピューティクス カンパニー リミテッド 抗ｐｄ―ｌ１抗体およびその用途
CN112867733B (zh) * 2018-10-19 2023-01-06 苏州丁孚靶点生物技术有限公司 抗cd137抗体及其应用
US20220064314A1 (en) * 2019-01-02 2022-03-03 Qlsf Biotherapeutics Inc. Cd137 agonist antibodies and uses thereof
CN114026120B (zh) * 2019-05-10 2024-03-19 礼进生物医药科技（上海）有限公司 人源化抗cd137抗体及其用途
CN112794905B (zh) * 2019-11-13 2022-10-04 合肥瀚科迈博生物技术有限公司 一种能够与人4-1bb结合的分子
CN117843786A (zh) * 2019-11-19 2024-04-09 非同（成都）生物科技有限公司 人源化4-1bb单克隆抗体及其药物组合物
CN113004415B (zh) * 2019-12-19 2022-09-30 合肥瀚科迈博生物技术有限公司 靶向her2和4-1bb的双特异性抗体及其应用
CN113004416B (zh) * 2019-12-19 2022-10-04 合肥瀚科迈博生物技术有限公司 靶向her2-cd137双特异性抗体的构建及其应用
WO2022121966A1 (en) * 2020-12-10 2022-06-16 Wuxi Biologics (Shanghai) Co., Ltd. An antibody against p-cadherin and uses thereof
CN112538116B (zh) * 2020-12-24 2022-11-25 东大生物技术(苏州)有限公司 一组4-1bb单克隆抗体及其医药用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1996029348A1 (en) * 1995-03-23 1996-09-26 Indiana University Foundation Monoclonal antibody against human receptor protein 4-1bb and methods of its use for treatment of diseases
WO1996032495A1 (en) * 1995-04-08 1996-10-17 Lg Chemicals Ltd. Monoclonal antibody specific for human 4-1bb and cell line producing same
NZ334691A (en) * 1996-10-11 2000-12-22 Bristol Myers Squibb Co Compositions of anti-4-1BB antibody effective for immunomodulation and treatment of T-cell autoimmune disease
US6037454A (en) * 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies

Also Published As

Publication number Publication date
CN1357009A (zh) 2002-07-03
CO5160384A1 (es) 2002-05-30
KR20000034847A (ko) 2000-06-26
KR20010101022A (ko) 2001-11-14
EP1131357A1 (en) 2001-09-12
AU1186900A (en) 2000-06-05
CN1187374C (zh) 2005-02-02
TWI230163B (en) 2005-04-01
WO2000029445A1 (en) 2000-05-25
AU757760B2 (en) 2003-03-06
CA2351170A1 (en) 2000-05-25
US6458934B1 (en) 2002-10-01
JP2002531383A (ja) 2002-09-24
AR021296A1 (es) 2002-07-03

Similar Documents

Publication Publication Date Title
PE20001316A1 (es) Anticuerpo humanizado especifico para 4-1bb humano y composicion farmaceutica que lo contiene
UA89017C2 (uk) ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b
RS52769B (sr) Kompozicije i postupci za povećanje mineralizacije kostiju
PE20090046A1 (es) Anticuerpo recombinante humanizado anti-interleuquina 10
CY1118709T1 (el) Αντιγονικα πεπτιδια του παραγοντα διεγερσης αποικιων των κοκκινοκυτταρων (gm-csf) και αντισωματα για ton gm-csf
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
DE60231651D1 (de) Proteinreinigungsverfahren
HK1077592A1 (zh) 改進型fc融合蛋白質
CY1107708T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα για υποδοχεα παραγοντα επιδερμικης αναπτυξης
ATE172743T1 (de) Nachweis von kollagenabbau -i(in vivo)
CO5700152A1 (es) Nuevos anticuerpos anti-igf-ir y sus usos
CR11030A (es) Proteinas de union, incluyendo anticuerpos, derivados de anticuerpos y fragmentos de anticuerpos, que se unen especificamente a cd154 y sus usos
WO2003034903A3 (en) Psma antibodies and protein multimers
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
HUP0202532A2 (hu) Ko-stimulátor szignál-transzdukciós molekula (AILIM) elleni humán monoklonális antitest és gyógyászati alkalmazása
ATE480562T1 (de) Veränderung von fcrn-bindungsaffinitäten oder von serumhalbwertszeiten von antikörpern mittels mutagenese
IN2009KN02655A (es)
RS54088B1 (en) B-CELL REDUCTION BY USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
ATE469176T1 (de) Modifizierter anti-tnf antikörper
ATE464374T1 (de) Assay zum schnellen nachweis vom humanen aktivierten protein c und hochspezifischer monoklonaler antikörper dagegen
ES2129487T3 (es) Peptidos sinteticos, anticuerpos dirigidos contra ellos y su utilizacion.
MXPA05009913A (es) Proteina enlazadora del receptor nogo.
ES2085993T3 (es) Proteina asociada a la pancreatitis aguda, medios para el diagnostico de la pancreatitis aguda.
MX2021012997A (es) Anticuerpos anti-c5 humanizados bifuncionales y proteínas de fusión del factor h y usos de los mismos.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed